Department of Biochemistry and Medical Chemistry, Pomeranian Medical University, Powstancow Wlkp. 72, 70-111, Szczecin, Poland.
Eur J Clin Pharmacol. 2012 Apr;68(4):371-7. doi: 10.1007/s00228-011-1131-3. Epub 2011 Oct 14.
Leflunomide (LEF) is a disease-modifying antirheumatic drug used for treating rheumatoid arthritis (RA) and the action of which may be modified by sex hormones. The aim of this study was to examine the association between CAG repeat polymorphism in the androgen receptor (AR) gene and the response to treatment with LEF in women with RA.
We studied 114 women diagnosed with RA and treated with LEF (20 mg daily). Follow-up was 12 months. CAG repeat polymorphism was determined using polymerase chain reaction (PCR) and subsequent fragment analysis by capillary electrophoresis.
Analysis revealed no statistically significant associations between CAG repeat polymorphism in the AR gene and improvement of disease activity parameters: erythrocyte sedimentation rate, serum C-reactive protein, patient's global assessment of disease activity on a visual analog scale (VAS), disease activity score of 28 joints (DAS28), and swollen and tender joint count.
Our results suggest no correlation between CAG repeat polymorphism in the AR gene and response to treatment with LEF in women with RA.
来氟米特(LEF)是一种用于治疗类风湿关节炎(RA)的疾病修饰抗风湿药物,其作用可能会受到性激素的影响。本研究的目的是研究雄激素受体(AR)基因中的 CAG 重复多态性与接受 LEF 治疗的 RA 女性患者的治疗反应之间的关系。
我们研究了 114 名被诊断为 RA 并接受 LEF(20mg/天)治疗的女性。随访时间为 12 个月。使用聚合酶链反应(PCR)和随后的毛细管电泳片段分析来确定 AR 基因中的 CAG 重复多态性。
分析显示,AR 基因中的 CAG 重复多态性与疾病活动参数的改善(红细胞沉降率、血清 C 反应蛋白、患者对疾病活动的视觉模拟量表评估、28 个关节疾病活动评分和肿胀和压痛关节计数)之间无统计学显著关联。
我们的结果表明,AR 基因中的 CAG 重复多态性与 RA 女性患者对 LEF 治疗的反应之间无相关性。